Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.

Modesitt SC, Jazaeri AA.

Expert Opin Pharmacother. 2007 Oct;8(14):2293-305. Review.

PMID:
17927484
2.

Management of recurrent ovarian carcinoma: current status and future directions.

Martin LP, Schilder RJ.

Semin Oncol. 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. Review.

PMID:
19332246
3.

Second-line treatment of ovarian cancer.

Markman M, Bookman MA.

Oncologist. 2000;5(1):26-35. Review.

4.

Investigational agents against platinum-resistant ovarian cancer.

Lorusso D, Ferrandina G, Fanfani F, Gagliardi ML, Scambia G.

Expert Opin Investig Drugs. 2007 Mar;16(3):325-36. Review.

PMID:
17302527
5.

Ovarian cancer: a focus on management of recurrent disease.

Herzog TJ, Pothuri B.

Nat Clin Pract Oncol. 2006 Nov;3(11):604-11. Review.

PMID:
17080178
6.

Therapy for recurrent ovarian cancer.

Kuhn WC.

Curr Womens Health Rep. 2003 Feb;3(1):33-8. Review.

PMID:
12521548
7.

Investigational agents for epithelial ovarian cancer.

Muggia F, Kosloff R.

Expert Rev Anticancer Ther. 2005 Oct;5(5):855-68. Review.

PMID:
16221055
8.

New-generation platinum drugs in the treatment of cisplatin-resistant cancers.

McKeage MJ.

Expert Opin Investig Drugs. 2005 Aug;14(8):1033-46. Review.

PMID:
16050795
9.

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y.

J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1.

PMID:
18830625
10.

Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.

Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, Donovan HS, Miller B, King M.

Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S44-8. doi: 10.1111/IGC.0b013e3181bf7fb8. Review.

PMID:
19955914
11.

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.

Colombo N, Gore M.

Crit Rev Oncol Hematol. 2007 Nov;64(2):129-38. Epub 2007 Jun 12. Review.

PMID:
17566758
12.

Emerging role of pemetrexed in ovarian cancer.

Tomao F, Panici PB, Frati L, Tomao S.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1727-35. doi: 10.1586/era.09.141. Review.

PMID:
19954283
13.

Drug resistance reversal--are we getting closer?

Baird RD, Kaye SB.

Eur J Cancer. 2003 Nov;39(17):2450-61. Review.

PMID:
14602131
14.

Pharmaceutical management of ovarian cancer : current status.

Markman M.

Drugs. 2008;68(6):771-89. Review.

PMID:
18416585
16.

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.

Gynecol Oncol. 2009 Jul;114(1):48-52. doi: 10.1016/j.ygyno.2009.03.001. Epub 2009 Apr 10.

PMID:
19361839
17.

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.

Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28.

PMID:
19179095
18.

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

Stordal B, Pavlakis N, Davey R.

Cancer Treat Rev. 2007 Dec;33(8):688-703. Epub 2007 Sep 18. Review.

PMID:
17881133
19.

Targeted therapies: tailored treatment for ovarian cancer: are we there yet?

Sessa C, Del Conte G.

Nat Rev Clin Oncol. 2010 Feb;7(2):80-2. doi: 10.1038/nrclinonc.2009.233. No abstract available.

PMID:
20118979
20.

Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

Kurzeder C, Sauer G, Deissler H.

Curr Cancer Drug Targets. 2006 May;6(3):207-27. Review.

PMID:
16712458
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk